The Role of Mass Spectrometry for Safety Evaluation in the Drug Discovery Stage

• YAMAMOTO Toshinori

  Drug Safety Research & Development, Pfizer Global Research & Development, Nagoya Laboratories, Pfizer Inc.

Bibliographic Information

Other Title

• 創薬初期の安全性評価における質量分析の活用
• ソウヤク ショキ ノ アンゼンセイ ヒョウカ ニ オケル シツリョウ ブンセキ ノ カツヨウ

Abstract

Recent advances in drug discovery technologies require a paradigm shift in safety evaluation of drug candidates, especially with respect to their toxicological contribution at the early stage of drug discovery. In this context, new sciences and technologies should be implemented in the field of safety evaluation, and the numerous applications of mass spectrometry (MS) are thought to be one of the key approaches. In the present review, we have summarized the usability of MS and its practical applications in early safety evaluation.

Journal

• Journal of the Mass Spectrometry Society of Japan

  Journal of the Mass Spectrometry Society of Japan 56 (3), 143-149, 2008

  The Mass Spectrometry Society of Japan

Keywords

• Mass spectrometry
• Genome toxicology
• Toxicopanomics
• Toxicogenomics
• Toxicoproteomics
• Toxicometabonomics
• Biomarker
• Genotyping

Details

• CRID: 1390001206496791680
• NII Article ID: 10021086920
• NII Book ID: AN0010555X
• DOI: 10.5702/massspec.56.143
• ISSN: 18804225
• ISSN: 18843271
• ISSN: 13408097
• NDL BIB ID: 9541376
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I9541376
• Web Site: http://www.jstage.jst.go.jp/article/massspec/56/3/56_3_143/_pdf
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed